Surmodics traded at $27.64 this Tuesday April 9th, decreasing $15.34 or 35.69 percent since the previous trading session. Looking back, over the last four weeks, Surmodics lost 6.15 percent. Over the last 12 months, its price fell by 18.90 percent. Looking ahead, we forecast Surmodics to be priced at 27.08 by the end of this quarter and at 25.48 in one year, according to Trading Economics global macro models projections and analysts expectations.
Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.